The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

• Berkley A. Lynch

  Departments of Molecular and Cellular Biology and Bioinformatics and Target Discovery, UCB Research Inc., 840 Memorial Drive, Cambridge, MA 02139; Departments of In Vitro Pharmacology and CNS Pharmacology, UCB S.A., Pharma Sector, Chemin du Foriest, B-1420 Braine L'Alleud, Belgium; and Department of Pharmacology, University of Washington, D429 HSB, Box 357280, Seattle, WA 98195-7280

• Nathalie Lambeng

  Departments of Molecular and Cellular Biology and Bioinformatics and Target Discovery, UCB Research Inc., 840 Memorial Drive, Cambridge, MA 02139; Departments of In Vitro Pharmacology and CNS Pharmacology, UCB S.A., Pharma Sector, Chemin du Foriest, B-1420 Braine L'Alleud, Belgium; and Department of Pharmacology, University of Washington, D429 HSB, Box 357280, Seattle, WA 98195-7280

• Karl Nocka

  Departments of Molecular and Cellular Biology and Bioinformatics and Target Discovery, UCB Research Inc., 840 Memorial Drive, Cambridge, MA 02139; Departments of In Vitro Pharmacology and CNS Pharmacology, UCB S.A., Pharma Sector, Chemin du Foriest, B-1420 Braine L'Alleud, Belgium; and Department of Pharmacology, University of Washington, D429 HSB, Box 357280, Seattle, WA 98195-7280

• Patricia Kensel-Hammes

  Departments of Molecular and Cellular Biology and Bioinformatics and Target Discovery, UCB Research Inc., 840 Memorial Drive, Cambridge, MA 02139; Departments of In Vitro Pharmacology and CNS Pharmacology, UCB S.A., Pharma Sector, Chemin du Foriest, B-1420 Braine L'Alleud, Belgium; and Department of Pharmacology, University of Washington, D429 HSB, Box 357280, Seattle, WA 98195-7280

• Sandra M. Bajjalieh

  Departments of Molecular and Cellular Biology and Bioinformatics and Target Discovery, UCB Research Inc., 840 Memorial Drive, Cambridge, MA 02139; Departments of In Vitro Pharmacology and CNS Pharmacology, UCB S.A., Pharma Sector, Chemin du Foriest, B-1420 Braine L'Alleud, Belgium; and Department of Pharmacology, University of Washington, D429 HSB, Box 357280, Seattle, WA 98195-7280

• Alain Matagne

  Departments of Molecular and Cellular Biology and Bioinformatics and Target Discovery, UCB Research Inc., 840 Memorial Drive, Cambridge, MA 02139; Departments of In Vitro Pharmacology and CNS Pharmacology, UCB S.A., Pharma Sector, Chemin du Foriest, B-1420 Braine L'Alleud, Belgium; and Department of Pharmacology, University of Washington, D429 HSB, Box 357280, Seattle, WA 98195-7280

• Bruno Fuks

  Departments of Molecular and Cellular Biology and Bioinformatics and Target Discovery, UCB Research Inc., 840 Memorial Drive, Cambridge, MA 02139; Departments of In Vitro Pharmacology and CNS Pharmacology, UCB S.A., Pharma Sector, Chemin du Foriest, B-1420 Braine L'Alleud, Belgium; and Department of Pharmacology, University of Washington, D429 HSB, Box 357280, Seattle, WA 98195-7280

抄録

Here, we show that the synaptic vesicle protein SV2A is the brain binding site of levetiracetam (LEV), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy. The LEV-binding site is enriched in synaptic vesicles, and photoaffinity labeling of purified synaptic vesicles confirms that it has an apparent molecular mass of ≈90 kDa. Brain membranes and purified synaptic vesicles from mice lacking SV2A do not bind a tritiated LEV derivative, indicating that SV2A is necessary for LEV binding. LEV and related compounds bind to SV2A expressed in fibroblasts, indicating that SV2A is sufficient for LEV binding. No binding was observed to the related isoforms SV2B and SV2C. Furthermore, there is a high degree of correlation between binding affinities of a series of LEV derivatives to SV2A in fibroblasts and to the LEV-binding site in brain. Finally, there is a strong correlation between the affinity of a compound for SV2A and its ability to protect against seizures in an audiogenic mouse animal model of epilepsy. These experimental results suggest that SV2A is the binding site of LEV in the brain and that LEV acts by modulating the function of SV2A, supporting previous indications that LEV possesses a mechanism of action distinct from that of other antiepileptic drugs. Further, these results indicate that proteins involved in vesicle exocytosis, and SV2 in particular, are promising targets for the development of new CNS drug therapies.

収録刊行物

• Proceedings of the National Academy of Sciences

  Proceedings of the National Academy of Sciences 101 (26), 9861-9866, 2004-06-21

  Proceedings of the National Academy of Sciences

キーワード

• Multidisciplinary

詳細情報

• CRID: 1363670318509134080
• NII論文ID: 80016813379
• DOI: 10.1073/pnas.0308208101
• ISSN: 10916490
• ISSN: 00278424
• Web Site: https://pnas.org/doi/pdf/10.1073/pnas.0308208101
• データソース種別:
  • Crossref
  • CiNii Articles